FDA Focuses ANDA Reviews on Basis of Risk
This article was originally published in The Gold Sheet
Executive Summary
A risk-ranking pilot went so well that FDA’s Office of Generic Drugs has swiftly expanded use of the technique to help focus the attention of reviewers, swamped by GDUFA deadline-studded, QbD-packed ANDAs, on the quality issues that will have the greatest impact on patient safety.
You may also be interested in...
FDA Builds Quality Dashboard To Focus CMC Reviews And Inspections On Greatest Risks
A dashboard tool US FDA is developing promises to liberate key information from the agency’s trove of CMC review documents, enabling greater consistency among reviews and a greater emphasis on the manufacturing issues that pose the greatest risks.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.